Netflix, Inc. (NASDAQ:NFLX) shares increased 0.46% in last trading session and ended the day at $110.23. NFLX Gross Margin is 32.30% and its has a return on assets of 2.40%. Netflix, Inc. (NASDAQ:NFLX) quarterly performance is -4.82%.
Netflix, Inc. (NASDAQ:NFLX) posted a quarterly profit of $29.4 million, or $0.07 per share, compared to $59.3 million, or $0.14 per share, in the year-ago period. Its revenue climbed to $1.74 billion from $1.41 billion. However, analysts were expecting earnings of $0.08 per share on revenue of $1.75 billion.
A. Schulman, Inc. (NASDAQ:SHLM) ended the last trading day at $37.98. Company weekly volatility is calculated as 2.11% and price to cash ratio as 10.40. A. Schulman, Inc. (NASDAQ:SHLM) showed a weekly performance of 5.94%.
A. Schulman, Inc. (NASDAQ:SHLM) expects to release fiscal 2015 fourth-quarter results after the market closes on Tuesday, October 20, 2015. The Company will hold its fiscal 2015 fourth-quarter earnings conference call on Wednesday, October 21, 2015 at 10 a.m. Eastern Time, with Bernard Rzepka, President and Chief Executive Officer and Joseph Levanduski, Executive Vice President and Chief Financial Officer.
On 14 October, R.R. Donnelley & Sons Company (NASDAQ:RRD) shares moved down -0.31% and was closed at $16.05. RRD EPS growth in last 5 year was 45.60%. R.R. Donnelley & Sons Company (NASDAQ:RRD) year to date (YTD) performance is -0.06%.
R. R. Donnelley & Sons Company (NASDAQ:RRD), a leader in providing multichannel communications, announced that it showcased its expansive portfolio of direct response communication products, services and solutions at &THEN, the Direct Marketing Association’s annual event, October 4-6 at the Boston Convention Center in Boston, Mass.
Forward Pharma A/S (NASDAQ:FWP) shares moved down -5.77% in last trading session and ended the day at $24.98. FWP has a return on assets of -40.00%. Forward Pharma A/S (NASDAQ:FWP) quarterly performance is -35.82%.
Leerink Swann reaffirmed their outperform rating on shares of Forward Pharma A/S (NASDAQ:FWP) in a research note issued to investors on Tuesday morning, Market Beat Ratings reports. Leerink Swann currently has a $43.00 price objective on the stock, down from their prior price objective of $46.00.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) caters to the Healthcare space. It has a net profit margin of -85.60% and weekly performance is 5.65%. On the last day of trading company shares ended up at $8.23. Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) distance from 50-day simple moving average (SMA50) is -6.68%.
Infinity Pharmaceuticals, Inc. (NASDAQ:INFI) will provide an update on the clinical development program and commercial overview for duvelisib, an oral, dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, and discuss the company’s immuno-oncology development candidate, IPI-549, at its Research and Development (R&D) Day this morning from 8:00am (ET) to 11:45am (ET) in New York City. During today’s presentations, Infinity will review its anticipated timelines for the development and commercialization of duvelisib. The company recently announced that the 120th patient has been enrolled in DYNAMO™, a Phase 2 study in patients with refractory indolent non-Hodgkin lymphoma (iNHL), and topline data from this study are anticipated in the third quarter of 2016.
Leave a Reply